Gastrointestinal treatments company Tranzyme Pharma (NASDAQ:TZYM) has secured $9.3 million in financing — enough to carry the company through the third quarter. Durham, North Carolina-based Tranzyme said that the loan came from an amendment and restatement of its existing debt financing facility with Oxford Finance and Horizon Technology Finance Corporation (NASDAQ:HRZN). Tranzyme will use a […]
Bristol-Myers Squibb (NYSE:BMY) is extending a drug discovery and development agreement with Tranzyme Pharma (NASDAQ:TZYM) to buy more time to continue the search for new drug candidates. Durham, North Carolina-based Tranzyme is entitled to up to $80 million in milestone payments for each drug program that results from the collaboration that is now set to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Gilead Sciences (NASDAQ:GILD) executive Dr. Franck Rousseau has been named chief medical officer of gastrointestinal drug development company Tranzyme Pharma (NASDAQ:TZYM). Rousseau will oversee Durham, North Carolina-based Tranzyme’s drug portfolio including two clinical-stage candidates ulimorelin and TZP-102. Ulimorelin is studied in a phase 3 clinical trial as a drug that can help restore GI function […]
Former Roche executive George Abercrombie is joining the board of directors of Tranzyme Pharma (NASDAQ:TZYM). Durham, North Carolina-based Tranzyme, which focuses on gastrointestinal treatments, will tap the more than 30 years of experience of Abercrombie, who was president and CEO of Roche’s North American pharmaceuticals operations from 2001 through 2009. Tranzyme does not yet have […]
Gastrointestinal drug development company Tranzyme Pharma (NASDAQ:TZYM) is searching for a chief medical officer to replace a departing executive. After the close of the markets, Tranzyme announced that Dr. Gordana Kosutic, Tranzyme’s vice president of clinical and regulatory affairs, is resigning effective Sept. 30 “to pursue another opportunity.” No other details on Kosutic’s new position […]
Tranzyme Pharma (NASDAQ:TZYM) likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. The Research Triangle Park, North Carolina company’s stock price closed at $4 per share, the same price for the stock as when Tranzyme’s shares started trading on Monday morning. During the […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
North Carolina’s next initial public offering will be Tranzyme Pharma, which expects to begin trading April 4. The company announced the date for the offering late today after earlier revising the terms of the IPO, lowering the target stock price to $4 per share. The Durham, North Carolina drug development company had initially planned to […]